A5019426741- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Immunology Research
- Advanced Thermodynamic Systems and Engines
- SARS-CoV-2 detection and testing
- Infection Control and Ventilation
- Dental Research and COVID-19
- COVID-19 Clinical Research Studies
- Computational Drug Discovery Methods
- RNA and protein synthesis mechanisms
- thermodynamics and calorimetric analyses
- interferon and immune responses
- Virus-based gene therapy research
- Animal Virus Infections Studies
- Infectious Encephalopathies and Encephalitis
- Spacecraft and Cryogenic Technologies
- Long-Term Effects of COVID-19
Rega Institute for Medical Research
2020-2025
KU Leuven
2020-2025
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan December 2019. With no specific therapeutic and prophylactic options available, virus has infected millions of people which more than half a million succumbed to viral disease, COVID-19. The urgent need for an effective treatment together with lack small animal infection models led clinical trials using repurposed drugs without preclinical evidence their vivo efficacy. We...
Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease. In this regard, main protease (3CL-Pro), also termed M-Pro, attractive drug target as it plays a central role in viral replication by processing polyproteins pp1a pp1ab at multiple distinct cleavage sites. We here report results program involving 8.7 K compounds containing marketed drugs, clinical preclinical candidates, small molecules...
Abstract SARS-CoV-2 rapidly spread around the globe after its emergence in Wuhan December 2019. With no specific therapeutic and prophylactic options available, virus was able to infect millions of people. To date, close half a million patients succumbed viral disease, COVID-19. The high need for treatment options, together with lack small animal models infection has led clinical trials repurposed drugs before any preclinical vivo evidence attesting their efficacy available. We used Syrian...
The COVID-19 pandemic has had an unprecedented impact on global health and the world's economies. Proliferation of virulent deadly SARS-CoV-2 variants require effective transmission mitigation strategies. Under reasonable environmental conditions, culturable infectious can survive contaminated fomites from hours to months. In present study we evaluated a surface-anchored polymeric quaternary ammonium antimicrobial help reduce fomite surfaces.Two studies were performed pre-treated metal disks...
Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting annually in ~219,000 deaths and a societal cost ~USD 60 billion, no antivirals or vaccines available. Here, we assess anti-norovirus activity new peptidomimetic aldehydes related to protease inhibitor rupintrivir. The early hit compound 4 inhibited replication murine norovirus (MNV) HuNoV GI.1 replicon vitro (EC50 ~1 µM) swiftly cleared from cells. Compound still inhibits proteolytic activity. We selected...
Abstract Compound repurposing is an important strategy for the identification of effective treatment options against SARS-CoV-2 infection and COVID-19 disease. In this regard, main protease (3CL-Pro), also termed M-Pro, attractive drug target as it plays a central role in viral replication by processing polyproteins pp1a pp1ab at multiple distinct cleavage sites. We here report results program involving 8.7 K compounds containing marketed drugs, clinical preclinical candidates, small...
Human norovirus is the main cause of viral gastroenteritis, resulting annually in ∼ 700 million infections and 200,000 deaths, whom most are children <5 years. Mouse norovirus-infected macrophages widely used vitro system to screen characterize antiviral effect norovirus-targeting small molecules. We have previously established assays using this system, identified novel inhibitors performed additional studies order a first insight into their mechanism action. After identification...
Human norovirus is the main cause of viral gastroenteritis, resulting annually in ∼ 700 million infections and 200,000 deaths, whom most are children <5 years. Mouse norovirus-infected macrophages widely used vitro system to screen characterize antiviral effect norovirus-targeting small molecules. We have previously established assays using this system, identified novel inhibitors performed additional studies order a first insight into their mechanism action. As potent safe anti-norovirus...
A commercially available and EPA/PMRA registered quaternary ammonium antimicrobial formulation was applied to stainless steel carrier disks sent two virology research institutes independently determine whether samples treated with SiQAC-C18 material could deactivate deposited SARS-CoV-2 virions on contaminated surfaces. The results support a sustained antiviral effect imparted from these surfaces by both virion destruction degradation of viral RNA. These preliminary indicate the SiQAC-18...
Human noroviruses (HuNoVs) are the most common cause of viral gastroenteritis resulting in ~219,000 deaths annually and a societal cost ~USD60 billion. There no antivirals or vaccines available to treat and/or prevent HuNoV. In this study, we performed large-scale phenotypical antiviral screening using mouse norovirus (MNV), which included ~1000 drug-like small molecules from Drug Design Synthesis Centre (Sapienza University, Rome). Compound...
A commercially available and EPA/PMRA registered quaternary ammonium antimicrobial formulation was applied to stainless steel carrier disks sent two virology research institutes independently determine whether samples treated with SiQAC-C18 material could deactivate deposited SARS-CoV-2 virions on contaminated surfaces. The results support a sustained antiviral effect imparted from these surfaces by both virion destruction degradation of viral RNA. These preliminary indicate the SiQAC-18...